These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26826182)

  • 41. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.
    Yan Z; Jin S; Wei Z; Huilian H; Zhanhai Y; Yue T; Juan L; Jing L; Libo Y; Xu L
    Biochim Biophys Acta; 2014 Sep; 1842(9):1350-63. PubMed ID: 24787381
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
    Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
    Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma.
    Park JW; Lee YS; Kim JS; Lee SK; Kim BH; Lee JA; Lee NO; Kim SH; Hong EK
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):1973-83. PubMed ID: 25842034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New targetable oncogenes in non-small-cell lung cancer.
    Oxnard GR; Binder A; Jänne PA
    J Clin Oncol; 2013 Mar; 31(8):1097-104. PubMed ID: 23401445
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation.
    Zhang Y; Su J; Yu J; Bu X; Ren T; Liu X; Yao L
    J Bone Miner Res; 2011 Mar; 26(3):604-17. PubMed ID: 20734453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic modifiers of EGFR dependence in non-small cell lung cancer.
    Sharifnia T; Rusu V; Piccioni F; Bagul M; Imielinski M; Cherniack AD; Pedamallu CS; Wong B; Wilson FH; Garraway LA; Altshuler D; Golub TR; Root DE; Subramanian A; Meyerson M
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18661-6. PubMed ID: 25512530
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
    Terai H; Tan L; Beauchamp EM; Hatcher JM; Liu Q; Meyerson M; Gray NS; Hammerman PS
    ACS Chem Biol; 2015 Dec; 10(12):2687-96. PubMed ID: 26390252
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A new target for therapy in squamous cell carcinoma of the lung.
    Ohashi K; Pao W
    Cancer Discov; 2011 Jun; 1(1):23-4. PubMed ID: 22586316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis.
    Zhang S; Bu X; Zhao H; Yu J; Wang Y; Li D; Zhu C; Zhu T; Ren T; Liu X; Yao L; Su J
    J Pathol; 2014 Mar; 232(4):436-48. PubMed ID: 24293323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.
    Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Lee SH; Kim SJ; Yoon HK; Kim TJ; Lee KY
    PLoS One; 2015; 10(11):e0142306. PubMed ID: 26555338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ubiquitin ligase Cbl-b acts as a negative regulator in discoidin domain receptor 2 signaling via modulation of its stability.
    Yu J; Zhao H; Zhang Y; Liu YC; Yao L; Li X; Su J
    FEBS Lett; 2014 May; 588(9):1509-14. PubMed ID: 24631539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.